Decision to Review On-site Data that Was Remotely Monitored Up to Sponsors, FDA Says
October 1, 2021
Sponsors should look to their own risk assessment models to determine if trial data that was monitored remotely should be re-examined once the pandemic eases and on-site monitoring visits resume, the FDA says in the latest revision of its guidance on conducting clinical trials during the COVID-19 pandemic.